Clinical Trial Update: Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of propranolol hydrochloride in combination with pembrolizumab for unresectable stage IIIC-IV cutaneous melanoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Propranolol Hydrochloride (propranolol hydrochloride)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 1, Phase 2 | Status: SUSPENDED